Previous Winners of the Capps Green Zomaya Award


The 7th Award was made jointly to Dr Alison Woolford and Dr Alessio Ciulli.

Dr Woolford received the Award in recognition of her work at Astex Pharmaceuticals on the application of fragment-based drug discovery to identify novel inhibitors of apoptosis proteins for the treatment of advanced cancer. She presented the 7th Memorial Lecture entitled: 'Fragment-based drug discovery applied to a protein-protein interaction target: from mM fragments to nM dual antagonist of XIAP and cIAP1'.

Dr Ciulli received the Award in recognition of his work at the University of Dundee on targeting protein-protein interactions involved in cancer; in particular the discovery of first-in-class molecules which disrupt the binding of Ubiquitin-related complexes; also for the engineering of highly selective BET inhibitors. He presented the 8th Memorial Lecture entitled 'Selective on-target chemical probes of protein-protein interactions' at the 28th Symposium on Medicinal Chemistry in Eastern England in April, 2017.


The 6th Award was presented to Dr Nicole Hamblin in recognition of her work at GlaxoSmithKline, UK, on the development of potent and selective inhibitors of phosphoinositide 3-kinase delta, for the treatment of asthma and chronic obstructive pulmonary diseases.  
Dr Hamblin presented the 6th Memorial Lecture entitled 'From bench to bedside: discovery and development of inhaled PI3 Kinase delta inhibitor GSK2269557 for the treatment of COPD'

Runner-up for the 6th Award. A runner-up award was made to Dr Lyn Jones for his work at Pfizer on the development of novel drugs to treat rare diseases such as cystic fibrosis, spinal muscular atrophy and muscular dystrophy. 


The 5th Award was presented to Dr James Scott in recognition of his work at AstraZeneca UK, on the discovery and development of novel compounds for the treatment of breast cancer, obesity, diabetes and glaucoma.

Dr Scott presented the 5th Memorial Lecture entitled 'Discovery of novel agonists of GPR119 for type II diabetes'.  


The 4th Award was presented to Dr Michael Waring  in recognition of his work at Astra Zeneca UK, in the application of medicinal chemistry to the selection of compounds for clinical evaluation in diabetes, cancer, cardiovascular and gastrointestinal diseases.

Dr Waring presented the 4th Memorial Lecture entitled 'Optimum Lipophilicity and Compound Quality - Strategies and Consequences for Lead Optimisation'.


The 3rd Award was presented to Professor Andrew Hopkins  in recognition of his work at Pfizer UK, on computer-aided drug discovery and its application to various drug classes, including novel inhibitors of HIV reverse transcriptase.

Professor Hopkins presented the 3rd Memorial Lecture entitled 'The Efficiency of Choice'.


The 2nd Award was presented to Dr Don Middleton in recognition of his contribution to a number of innovative projects at Pfizer UK, including the discovery of neurokinin antagonists and opioid agonists for the treatment of irritable bowel syndrome and serotonin re-uptake inhibitors for the treatment of psychotropic disorders.

Dr Middleton presented the 2nd Memorial Lecture entitled 'Designing short half-life selective serotonin re-uptake inhibitors'.


The inaugural Award was presented to Dr Jon Bentley  in recognition of his work at Cerebrus/Vernalis in developing novel compounds for the treatment of obesity.

Dr Bentley presented the 1st Memorial Lecture entitled 'Selective 5-HT2c agonists'.